Identification of Stage IIIC/IV EGFR-Mutated Non-Small Cell Lung Cancer Populations Sensitive to Targeted Therapy Based on a PET/CT Radiomics Risk Model

2020 ◽  
Author(s):  
Dan Shao ◽  
Dongyang Du ◽  
Haiping Liu ◽  
Jieqin Lv ◽  
You Cheng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Risk Model ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiic ◽  
Pet Ct ◽  
Egfr Mutated

Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy

2015 ◽  
Vol 12 (2) ◽  
pp. 63-66 ◽  
Author(s):  
Justine L Kuiper ◽  
Idris Bahce ◽  
Charlotte Voorhoeve ◽  
Maqsood Yaqub ◽  
Daniëlle AM Heideman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clonal Selection ◽  
Small Cell ◽  
Small Cell Lung ◽  
Egfr Mutated

Significance of Neutrophil-to-lymphocyte Ratio in Western Advanced EGFR-mutated Non-small Cell Lung Cancer Receiving a Targeted Therapy

2017 ◽  
Vol 103 (5) ◽  
pp. 443-448 ◽  
Author(s):  
Fausto Meriggi ◽  
Claudio Codignola ◽  
Giordano D. Beretta ◽  
Giovanni L. Ceresoli ◽  
Alberto Caprioli ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Neutrophil To Lymphocyte Ratio ◽  
Small Cell Lung ◽  
Lymphocyte Ratio ◽  
Caucasian Patients ◽  
Egfr Mutated

Purpose Lung cancer is one of the leading causes of cancer-related death worldwide and, although targeted therapy with tyrosine kinase inhibitors has dramatically improved the rates of response and survival in advanced EGFR-mutated adenocarcinoma, the overall outcome remains unsatisfactory. Therefore, new prognostic factors, preferably simple, inexpensive, and easy to reproduce on a large scale, are needed. We performed a retrospective analysis of our database including 63 western Caucasian patients with advanced EGFR-mutated lung adenocarcinoma and receiving gefitinib, erlotinib, or afatinib as first- or second-line therapy. Several studies demonstrated a strong link between elevated neutrophil-to-lymphocyte ratio (NLR) and poor prognosis both in early and advanced stages of non-small-cell lung cancer (NSCLC). Methods From January 2011 to December 2015, 63 consecutive elegible patients with advanced EGFR-mutated NSCLC were included in this analysis from 5 institutions. The NLR was derived from the absolute neutrophil and the absolute lymphocyte counts of a full blood count and the cutoff value was determined according to the mean NLR level. Results Despite the small sample analyzed, we found that NLR has a prognostic role for progression-free survival (PFS) and overall survival (OS), reaching a statistically significant difference with a better PFS and OS in the lower NLR group. Conclusions Pretreatment NLR seems to represent a reliable, simple, and easy to reproduce laboratory tool to predict outcome and response to cancer therapies in this setting of Western Caucasian patients with EGFR-mutated NSCLC.

scholarly journals Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer

2020 ◽  
Vol 48 (12) ◽  
pp. 030006052098020
Author(s):  
Kejun Liu ◽  
Guanming Jiang ◽  
Nianxin Fang ◽  
Limin Cai ◽  
Wei Du ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Prognostic Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Advanced Nsclc ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lymphocyte Ratio ◽  
Egfr Mutated

Objective To analyze the prognostic significance of the pretreatment platelet/lymphocyte ratio (PLR) for targeted therapy in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). Methods We conducted a retrospective study of 96 patients with EGFR-mutated advanced NSCLC who were treated at Dongguan People’s Hospital, Southern Medical University from May 2014 to December 2017. All patients received EGFR-targeted therapy until disease progression, unacceptable toxicity, or other factors. Approximately 3 days before the initial treatment, data including a detailed clinical history, physical examination, radiographic results, pathological diagnosis, and laboratory parameters including complete blood cell counts and albumin levels were evaluated. Results Patients in the PLR ≥ 190 group had shorter progression-free survival (PFS) than those in the PLR < 190 group. Furthermore, the 1-year PFS rate was worse in the PLR ≥ 190 group than in the PLR< 190 group. Multivariate analysis indicated the possible role of PLR as a prognostic factor for patients with advanced NSCLC who received EGFR-targeted therapy. Conclusions Pretreatment PLR may be an independent prognostic factor for patients with NSCLC receiving EGFR tyrosine kinase inhibitor treatment. Further studies are needed to identify the impact of PLR on EGFR-mutated NSCLC.

Sign in / Sign up

Export Citation Format

Share Document